Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of
all lung cancer cases. In spite of achievements in understanding the pathogenesis of this …

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor
receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic …

Cancer is associated with mutated genes, and analysis of tumour-linked genetic alterations
is increasingly used for diagnostic, prognostic and treatment purposes. The genetic profile of …

Osimertinib has been demonstrated to overcome the epidermal growth factor receptor
(EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR–tyrosine …

Advances in next-generation sequencing and bioinformatics have led to an unprecedented
view of the cancer genome and its evolution. Genomic studies have demonstrated the …

Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond
to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate …